Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...

Switching disease-modifying therapies (DMTs) for multiple sclerosis (MS) may improve your symptoms or reduce side effects, though sometimes new medications may not work as well or may cause different ...

The investment seeks long-term total return. The fund will seek to achieve its investment objective by investing principally in a portfolio of residential and commercial mortgage-backed securities and ...